CU22615A1 - Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos - Google Patents

Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Info

Publication number
CU22615A1
CU22615A1 CU1994080A CU1994080A CU22615A1 CU 22615 A1 CU22615 A1 CU 22615A1 CU 1994080 A CU1994080 A CU 1994080A CU 1994080 A CU1994080 A CU 1994080A CU 22615 A1 CU22615 A1 CU 22615A1
Authority
CU
Cuba
Prior art keywords
mammalian species
monoclonal antibodies
variable domains
less immunogenic
chimaeric antibodies
Prior art date
Application number
CU1994080A
Other languages
English (en)
Inventor
De Acosta Del Rio Cristina Maria Mateo
Valladares Josefa Lombardero
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU1994080A priority Critical patent/CU22615A1/es
Priority to ES95201752T priority patent/ES2220918T3/es
Priority to AT95201752T priority patent/ATE265531T1/de
Priority to EP95201752A priority patent/EP0699755B1/en
Priority to DK95201752T priority patent/DK0699755T3/da
Priority to DE69532940T priority patent/DE69532940T2/de
Priority to PT95201752T priority patent/PT699755E/pt
Priority to CA002153135A priority patent/CA2153135C/en
Priority to US08/497,312 priority patent/US5712120A/en
Priority to CNB951091484A priority patent/CN1279168C/zh
Priority to JP16651395A priority patent/JP3238049B2/ja
Publication of CU22615A1 publication Critical patent/CU22615A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se relaciona con la rama de la inmunología y en particular con un procedimiento de obtención de inmunoglobulinas menos inmunogénicas a partir de anticuerpos monoclonales murinos, y las formulaciones que contengan estas inmunoglobinas modificadas. De acuerdo con lo expuesto, el objeto de esta invención es proporcionar un método para la obtención de anticuerpos monoclonales modificados, generados a partir de linfocitos de ratón y que resulten menos inmunogénicos al utilizarse en humanos. La esencia de la invención consiste en romper la inmunogenicidad T de una inmunoglobulina murina, sustituyendo en los marcos (FRs) de la región variable de la misma aquellos aminoácidos que están involucrados en los epitopos T que se predicen con los diferentes algoritmos, por los residuos que se encuentran presentes en la misma posición, en la secuencia de una inmunoglobulina humana, sin afectar la afinidad de su unión con el antígeno. La reducción de la inmunogenicidad de los anticuerpos monoclonales murinos se comprenderá mejor a través de la siguiente descripción y ejemplos.
CU1994080A 1994-06-30 1994-06-30 Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos CU22615A1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU1994080A CU22615A1 (es) 1994-06-30 1994-06-30 Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
ES95201752T ES2220918T3 (es) 1994-06-30 1995-06-27 Metodo para obtencion de inmunoglobulinas modificadas con inmunogenicidad reducida de dominios variables de un anticuerpo murino y composiciones que los contienen.
AT95201752T ATE265531T1 (de) 1994-06-30 1995-06-27 Verfahren zur herstellung modifizierter immunoglobulinen mit reduzierter immunogenität der variablen domänen einer murinen antikörpers, zusammensetzungen die diese enthalten
EP95201752A EP0699755B1 (en) 1994-06-30 1995-06-27 Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them
DK95201752T DK0699755T3 (da) 1994-06-30 1995-06-27 Fremgangsmåde til opnåelse af modificerede immunglobuliner med reduceret immunogenicitet af variable domæner i et murint antistof, præparater der indeholder disse
DE69532940T DE69532940T2 (de) 1994-06-30 1995-06-27 Verfahren zur Herstellung modifizierter Immunoglobuline mit verminderter Immunogenität der variablen Domänen eines Antikörpers der Maus, Zusammensetzungen, die diese enthalten
PT95201752T PT699755E (pt) 1994-06-30 1995-06-27 Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem
CA002153135A CA2153135C (en) 1994-06-30 1995-06-30 Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains and compositions containing them
US08/497,312 US5712120A (en) 1994-06-30 1995-06-30 Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them
CNB951091484A CN1279168C (zh) 1994-06-30 1995-06-30 得到经过修饰降低了鼠抗体可变区之免疫原性的免疫球蛋白的方法及含有免疫球蛋白的组合物
JP16651395A JP3238049B2 (ja) 1994-06-30 1995-06-30 マウス抗体可変部ドメインの免疫原性を減弱させた修飾免疫グロブリンの取得方法およびそれらを含有する組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1994080A CU22615A1 (es) 1994-06-30 1994-06-30 Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Publications (1)

Publication Number Publication Date
CU22615A1 true CU22615A1 (es) 2000-02-10

Family

ID=5459314

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1994080A CU22615A1 (es) 1994-06-30 1994-06-30 Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Country Status (11)

Country Link
US (1) US5712120A (es)
EP (1) EP0699755B1 (es)
JP (1) JP3238049B2 (es)
CN (1) CN1279168C (es)
AT (1) ATE265531T1 (es)
CA (1) CA2153135C (es)
CU (1) CU22615A1 (es)
DE (1) DE69532940T2 (es)
DK (1) DK0699755T3 (es)
ES (1) ES2220918T3 (es)
PT (1) PT699755E (es)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
BR9710811A (pt) 1996-05-22 1999-08-17 Novopharm Biotech Inc Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
EP0909277B2 (en) 1996-06-07 2008-12-24 Poniard Pharmaceuticals, Inc. Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
EP0946727B1 (en) * 1996-11-27 2007-01-24 Genentech, Inc. Antibody mutants
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US7115722B1 (en) 1997-05-22 2006-10-03 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6936249B1 (en) 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
CN1318092C (zh) * 1998-04-15 2007-05-30 利思进药品公司 含有抗体-细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
CU22921A1 (es) * 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
CA2409361A1 (en) * 2000-05-19 2001-11-22 Scancell Limited Humanised antibodies to the epidermal growth factor receptor
CZ2003214A3 (cs) * 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CN1491232A (zh) * 2001-02-06 2004-04-21 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰肥胖蛋白
JP4279554B2 (ja) * 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング T細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
WO2002066058A1 (en) * 2001-02-19 2002-08-29 Merck Patent Gmbh Modified anti-egfr antibodies with reduced immunogenicity
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20020197253A1 (en) * 2001-05-22 2002-12-26 Cheek Dennis J. Compositions and methods for promoting or inhibiting NDPK
EP1395274A2 (en) * 2001-05-22 2004-03-10 Duke University Compositions and methods for inhibiting metastasis
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
WO2003018749A2 (en) 2001-08-22 2003-03-06 Shengfeng Li Compositions and methods for generating antigen-binding units
US7175983B2 (en) 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
AU2002351957B2 (en) * 2001-11-12 2009-09-03 Merck Patent Gmbh Modified anti-TNF alpha antibody
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
EP1644416A4 (en) * 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
EP1694706B1 (en) * 2003-11-01 2012-04-04 Merck Patent GmbH Modified anti-cd52 antibody
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
JP2007512846A (ja) * 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Il-7 융합 단백질
EP1699821B1 (en) * 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
CA2555306A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
ZA200608572B (en) * 2004-04-16 2008-06-25 Genentech Inc Assay for antibodies
EP1797176A2 (en) * 2004-09-09 2007-06-20 University of Washington All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
CA2596833C (en) * 2005-02-03 2016-04-12 Antitope Limited Human antibodies and proteins
EP1869192B1 (en) * 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
AU2006226192A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
PE20070374A1 (es) * 2005-07-08 2007-05-12 Pfizer Ltd ANTICUERPOS ANTI-MAdCAM
JP2009502195A (ja) * 2005-08-04 2009-01-29 セントカー・インコーポレーテツド 抗TNFα抗体および使用方法
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
JPWO2007049770A1 (ja) 2005-10-28 2009-04-30 明治製菓株式会社 緑膿菌の外膜タンパク質pa5158
AU2006332155B2 (en) * 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
KR20080113239A (ko) 2006-03-30 2008-12-29 메이지 세이카 가부시키가이샤 녹농균의 외막 단백질 pa0427
DK2038306T3 (en) 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
AU2007301599B2 (en) * 2006-09-28 2013-01-10 Merck Serono S.A. Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
MY154819A (en) 2006-12-26 2015-07-31 Centro Inmunologia Molecular Pharmaceutical compositions with capacity to induce adoptosis in tumor cells for the diagnosis and treatment of the b-cell chroniclymphocytic leukemia
NZ578635A (en) * 2006-12-26 2012-03-30 Ct De Inmunolgia Molecular Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20100291070A1 (en) 2007-12-25 2010-11-18 Meiji Seika Kaisha, Ltd. Type iii secretion system component protein pa1698 of pseudomonas aeruginosa
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
JPWO2009119794A1 (ja) 2008-03-27 2011-07-28 タカラバイオ株式会社 感染症予防、治療剤
US8420092B2 (en) 2009-03-19 2013-04-16 Ben-Gurion University Of The Negev Research And Development Authority Method of treating diabetes by administering an anti-NKp46 antibody
WO2010125566A2 (en) 2009-04-27 2010-11-04 Technion Research And Development Foundation Ltd. Markers for cancer detection
US8859736B2 (en) 2010-02-19 2014-10-14 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
US9485812B2 (en) 2010-07-08 2016-11-01 Honda Motor Co., Ltd. High frequency heating coil
US9675693B2 (en) 2010-09-30 2017-06-13 Riken Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
EP3222635A1 (en) 2010-12-21 2017-09-27 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
WO2012090939A1 (ja) 2010-12-27 2012-07-05 国立大学法人名古屋大学 受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法
US9555108B2 (en) 2011-03-24 2017-01-31 Texas Tech University System TCR mimic antibodies as vascular targeting tools
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
ES2748577T3 (es) 2011-05-19 2020-03-17 Univ Michigan Regents Agentes de fijación de la integrina alfa-2 y uso de los mismos para inhibir la proliferación de las células de cáncer
EP2743699A4 (en) 2011-08-12 2015-04-08 Nat Inst Infectious Diseases METHOD FOR TESTING, PREVENTING AND TREATING INFECTIOUS DISEASE ASPERGILLUS FUMIGATUS AND COMPOSITION
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
WO2013140393A1 (en) 2012-03-21 2013-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peptides derived from the d1 - domain of nkp46
US9416189B2 (en) 2012-05-11 2016-08-16 Microbial Chemistry Research Foundation Anti-CXADR antibody
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
AU2013297478B2 (en) 2012-07-30 2018-12-20 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody against human midkine
WO2014036562A2 (en) 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
HK1212236A1 (en) 2012-09-05 2016-06-10 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
EP2896291B1 (en) 2012-09-13 2019-03-20 Chugai Seiyaku Kabushiki Kaisha Gene knock-in non-human animal
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
WO2014093855A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
WO2014123227A1 (ja) 2013-02-08 2014-08-14 株式会社医学生物学研究所 ヒトnrg1タンパク質に対する抗体
EP3339327A3 (en) 2013-02-28 2018-09-19 National Cancer Center Antibody against insoluble fibrin
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
WO2014174596A1 (ja) 2013-04-23 2014-10-30 株式会社医学生物学研究所 ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
WO2015068781A1 (ja) 2013-11-06 2015-05-14 国立大学法人大阪大学 インフルエンザウイルスa型のグループ1に対して広域な中和活性を有する抗体
EP3221349B1 (en) 2014-11-19 2020-11-04 Axon Neuroscience SE Humanized tau antibodies in alzheimer's disease
EP3331544A4 (en) 2015-08-07 2019-03-27 University Of Virginia Patent Foundation IDENTIFICATION OF CLASS 1 MHC ASSOCIATED GLYCOPEPTIDES AS OBJECTIVES TO CANCER IMMUNOTHERAPY
WO2017201731A1 (en) 2016-05-27 2017-11-30 Beijing Vdjbio Co., Ltd. Antibodies, composition and kits comprising same, and methods of use thereof
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
KR102607101B1 (ko) 2017-01-26 2023-11-29 제트엘아이피 홀딩 리미티드 Cd47 항원 결합 유닛 및 그것의 사용
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2019169015A1 (en) 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
AU2019244481A1 (en) 2018-03-28 2020-10-01 Axon Neuroscience Se Antibody-based methods of detecting and treating Alzheimer's disease
US20210355199A1 (en) 2018-06-28 2021-11-18 University Of Virginia Patent Foundation Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
CN112512584A (zh) 2018-07-27 2021-03-16 国立大学法人大阪大学 用于抑制衰老、预防、改善或治疗衰老相关疾病或症状、或者延长寿命的组合物
EP3854875B1 (en) 2018-09-21 2026-01-14 Institute of Science Tokyo Human monoclonal antibody binding specifically to human hmgb1, and pharmaceutical composition for treating or preventing alzheimer's disease containing said human monoclonal antibody
CA3115660A1 (en) 2018-10-12 2020-04-16 Hassan JUMAA-WEINACHT Monoclonal antibody composition for treatment of philadelphia chromosome positive acute lymphoblastic leukemia
EP4219550A1 (en) 2018-11-02 2023-08-02 Oklahoma Medical Research Foundation Monoclonal antibodies to eltd1 and uses thereof
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
WO2020176682A1 (en) 2019-02-26 2020-09-03 Equillium, Inc. Anti-cd6 antibody compositions and methods for treating lupus
CN115279789A (zh) 2019-12-06 2022-11-01 真和制药有限公司 破坏gal3和胰岛素受体或整联蛋白的相互作用的抗体及其使用方法
US12662535B2 (en) 2020-01-17 2026-06-23 Immunelogic Therapeutics, Inc. Pro-antibody that reduces off-target toxicity
JPWO2021200131A1 (es) 2020-03-30 2021-10-07
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US20240025985A1 (en) 2020-12-09 2024-01-25 National University Corporation Tokyo Medical And Dental University Agent for Preventing or Treating Frontotemporal Lobar Degeneration
JP2024526764A (ja) 2021-07-13 2024-07-19 トゥルーバインディング,インコーポレイテッド タンパク質凝集を防止する方法
US20230279120A1 (en) 2021-11-09 2023-09-07 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
TW202440647A (zh) 2021-11-19 2024-10-16 英商米羅比奧有限公司 經工程改造之pd-1抗體及其用途
CN119213128A (zh) 2022-03-09 2024-12-27 株式会社丘阿德 与Eva1蛋白质结合的人源化抗体或其功能性片段、抗体药物缀合物和嵌合抗原受体
WO2023196866A1 (en) 2022-04-06 2023-10-12 Mirobio Limited Engineered cd200r antibodies and uses thereof
JPWO2023238869A1 (es) 2022-06-07 2023-12-14
CN120456922A (zh) 2022-11-25 2025-08-08 国立大学法人大阪大学 针对血液癌的抗体
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
AR134368A1 (es) 2023-11-17 2026-01-07 Wuxi Biologics Ireland Ltd Anticuerpos anti-muc16 y usos de los mismos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NO873164L (no) 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
AU625613B2 (en) 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
JP2646007B2 (ja) 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 抗hiv抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗hivキメラ抗体ならびにその製法
CA1339198C (en) 1988-02-12 1997-08-05 Gregory Paul Winter Antibodies to the antigen campath-1
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
DE69233482T2 (de) * 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1993011794A1 (en) * 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
EP0586002B1 (en) * 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies

Also Published As

Publication number Publication date
DE69532940T2 (de) 2005-05-25
DE69532940D1 (de) 2004-06-03
PT699755E (pt) 2004-09-30
CN1279168C (zh) 2006-10-11
JP3238049B2 (ja) 2001-12-10
CA2153135A1 (en) 1995-12-31
ATE265531T1 (de) 2004-05-15
CA2153135C (en) 2005-06-07
EP0699755A3 (en) 1996-06-12
CN1133886A (zh) 1996-10-23
ES2220918T3 (es) 2004-12-16
JPH08280387A (ja) 1996-10-29
US5712120A (en) 1998-01-27
DK0699755T3 (da) 2004-08-30
EP0699755B1 (en) 2004-04-28
EP0699755A2 (en) 1996-03-06

Similar Documents

Publication Publication Date Title
EP0699755A3 (en) Process for obtaining modified immunoglobulins with reduced immunogenicity of the variable domains of a murine antibody, compositions containing them
KR880006357A (ko) 인터류킨-i에 대한 항체
ATE366747T1 (de) Menschliche monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor
DK0460076T3 (da) Genetisk manipulerede immunoglobuliner
PT918797E (pt) Imunoglobulina humanizada reactiva com integrina alfa4beta7
DE69638355D1 (de) Anti-CD3-Antikörper zur Verwendung zur Induzierung von Immunsuppression
ES2059719T3 (es) Mejoras relativas a anticuerpos.
ATE81153T1 (de) Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
ATE166883T1 (de) Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
DE68922842D1 (de) Testsystem zum nachweis von antikörpern und methode zur herstellung nichtmenschlicher immunantikörper.
YU22693A (sh) Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
AU635243B2 (en) Immunoassay of human osteocalcin, reagent and kit therefor, antihuman osteocalcin antibody, hybridoma producing said antibody, and method of producing said antibody
NO175639C (no) Peptid, antistoff oppnådd ved hjelp av peptidet, en fremgangsmåte for immunologisk bestemmelse av intakt prokollagen peptid (type III) og anvendelse av peptidet
PT733903E (pt) Processo de dosagem imunologica de cortisol nomeadamente urinario e reagentes utilizados
EP0845540A4 (en) MONOCLONAL ANTIBODIES AND ANTIGENS RELATED TO HUMAN LUNG ADENOCARCINOMA AND IMMUNOASSAY METHOD USING THE SAME
GB2199833A (en) Preparation of monoclonal antibodies
DK0476059T3 (da) Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
DE69610283D1 (de) Verfahren zur immunologischen Identifizierung oder Bestimmung von Polypeptid-Antigenen
ATE239754T1 (de) An nukleinsäure gebundenes polypeptid, verfahren zur herstellung eines an nukleinsäure gebundenen polypeptides und immunoassay, in dem dieses polypeptid verwendung findet
IT8821547A0 (it) Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo.